Author

Monika Skupińska

Observed names: M Skupinska, M. Skupinska, M. Skupińska, M.M. Skupinska, Monika Skupinska

Institution: Celon Pharma (Poland)

Observed institution: Celon Pharma (Poland)

OpenAlex ID: A5045102648

MET-Pyk2 Axis Mediates Acquired Resistance to FGFR Inhibition in Cancer Cells

2021 · Kamila Kitowska, Monika Gorska-Arcisz, et al. · Frontiers in Oncology · 30

PDF

FGFR1–4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer

2022 · Joanna Moes-Sosnowska, Monika Skupinska, et al. · International Journal of Molecular Sciences · 10

PDF

p38 Mediates Resistance to FGFR Inhibition in Non-Small Cell Lung Cancer

2021 · Izabela Zarczynska, Monika Gorska-Arcisz, et al. · Cells · 10

PDF

Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer

2024 · Delfina Popiel, Aleksandra Stańczak, et al. · Frontiers in Oncology · 7

550P Preclinical characterization of CPL304110 as a potential selective inhibitor of fibroblast growth factors 1/2/3 in solid cancers

2020 · D. Popiel, A. Mikołajczyk, et al. · Annals of Oncology · 2

The role of FGFR2 amplification and expression in patients with advanced or metastatic gastric cancer receiving fluoropyrimidine-based chemotherapy

2018 · M.M. Skupinska, M. Jesiotr, et al. · Annals of Oncology · 2

Abstract 3184: Development of an innovative bifunctional CPL976-MMAE conjugate based on a bispecific anti-PD-L1/ant-AXL antibody with a dual mechanism of action

2024 · Krysztof Lacek, Anna Jablonska, et al. · Cancer Research · 1

46O Preliminary results from a phase IA trial of selective FGFR1-3 inhibitor CPL304110 in patients with FGFR-deregulated advanced solid malignancies

2023 · I. Lugowska, A. Stanczak, et al. · ESMO Open · 1

PDF

712P Analysis of fibroblast growth factor receptor 3 aberrations in bladder cancer, for enabling personalized and effective therapy based on FGFR inhibitor

2021 · R. Sosnowski, D. Popiel, et al. · Annals of Oncology · 1

1409P Comparing different methods of FGFR1 aberrations analysis in squamous cell lung cancer (SqCLC) targeted therapy

2020 · M.M. Skupinska, T. Obtulowicz, et al. · Annals of Oncology · 1

47P Integration of miRNA profiles and p53 mutations as biomarkers for predicting sensitivity and resistance to FGFR inhibitor CPL110 in cancer therapy

2024 · M.M. Skupinska, M. Walczak, et al. · ESMO Open

Abstract 5084: A first-in-class bispecific antibody CPL976 with a dual PD-L1/AXL mechanism of action that promotes common biological antitumor effects in in vitro and in vivo models

2024 · Delfina Popiel, Damian Kołakowski, et al. · Cancer Research

Analysing the molecular landscape of squamous cell carcinoma through simultaneous targeted DNA and RNA-based next-generation sequencing

2022 · J Moes-Sosnowska, M Skupinska, et al. · European Respiratory Journal

EP16.03-014 Simultaneous Detection of FGFR Gene Aberrations in Squamous Non-small Cell Lung Cancer Using Targeted DNA- and RNA-based NGS

2022 · J. Moes-Sosnowska, M. Skupinska, et al. · Journal of Thoracic Oncology

PDF

FGFR1 gene aberrations and FGFR1 protein expression in squamous non-small cell lung cancer (Sq-NSCLC)

2021 · Joanna Moes-Sosnowska, Adriana Rozy, et al. · European Respiratory Journal

P35.08 RNA-Based Gene Alteration and Expression Analysis in Sq-NSCLC with known FGFR1 Amplification and Protein Expression Status

2021 · J. Moes-Sosnowska, A. Rozy, et al. · Journal of Thoracic Oncology

PDF

Molecular profiling of Sq-NSCLC with enhanced FGFR1-4 and MET gene expression – NGS pilot study

2020 · Joanna Moes-Sosnowska, Ewa Szczepulska-Wojcik, et al. · European Respiratory Journal

P3.02-051 Low Consistency Between FGFR1 Gene Amplification and Protein Expression in Squamous Cell Lung Cancer (SQCLC)

2017 · J. Chorostowska-Wynimko, M. Skupinska, et al. · Journal of Thoracic Oncology

Therapeutic potential of CPL-407-105 – Novel potent JAK/STAT pathway inhibitor for the treatment of asthma

2014 · Pawel Gunerka, Barbara Dymek, et al. · European Respiratory Journal

Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders

2014 · Pawel Gunerka, Barbara Dymek, et al. · European Respiratory Journal

1048 Gene Silencing of -catenin Inhibits Growth of Wnt/ß-catenin Pathway Dependent Colon Cancer Cell Lines

2012 · A. Bujak, M. Matloka, et al. · European Journal of Cancer

Works count: 21

Citation count: 65

H-index: 4

I10-index: 3